Tripartite Motif Containing 65 Deficiency Confers Protection Against Acute Kidney Injury via Alleviating Voltage-Dependent Anion Channel 1–Mediated Mitochondrial Dysfunction

Abstract

Acute kidney injury (AKI) is a prevalent and serious clinical disease with a high incidence rate and significant health burden. The limited understanding of the complex pathological mechanisms has hindered the development of efficacious therapeutics. Tripartite motif containing 65 (TRIM65) has recently been identified as a key regulator of acute inflammation. However, its role in AKI remains unclear. The present study observed that TRIM65 expression was upregulated in AKI. Moreover, the knockout of the Trim65 gene in mice exhibited a substantial protective impact against rhabdomyolysis, ischemia-reperfusion (I/R), and cisplatin-induced AKI. Mechanistically, TRIM65 directly binds and mediates K48/K63-linked polyubiquitination modifications of voltage-dependent anion channel 1 (VDAC1) at its K161 and K200 amino acid sites. TRIM65 plays a role in maintaining the stability of VDAC1 and preventing its degradation by the autophagy pathway. TRIM65 deficiency attenuates mitochondrial dysfunction in renal tubular epithelial cells during AKI. Conversely, the overexpression of VDAC1 in renal tissues has been demonstrated to negate the protective effect of TRIM65 deficiency on AKI. These findings suggest that TRIM65 may play a role regulating of AKI through the targeting of VDAC1-dependent mitochondrial function, offering potential avenues for the development of new drug targets and strategies for the treatment of AKI.

Keywords

acute kidney injury (AKI) / mitochondrial dysfunction / tripartite motif containing 65 (TRIM65) / ubiquitination / voltage-dependent anion channel 1 (VDAC1)

References

[1] S. R. Gonsalez, A. L. Cortes, R. C. D. Silva, J. Lowe, M. C. Prieto, and L. D. Silva Lara, “Acute Kidney Injury Overview: From Basic Findings to New Prevention and Therapy Strategies,” Pharmacology & Therapeutics 200 (2019): 1-12.

[2] C. Ronco, R. Bellomo, and J. A. Kellum, “Acute Kidney Injury,” Lancet 394, no. 10212 (2019): 1949-1964.

[3] A. Abebe, K. Kumela, M. Belay, B. Kebede, and Y. Wobie, “Mortality and Predictors of Acute Kidney Injury in Adults: A Hospital-Based Prospective Observational Study,” Scientific Reports 11, no. 1 (2021): 15672.

[4] J. A. Kellum, P. Romagnani, G. Ashuntantang, C. Ronco, A. Zarbock, and H. J. Anders, “Acute Kidney Injury,” Nature Reviews Disease Primers 7, no. 1 (2021): 52.

[5] Q. Zhang, T. Sun, F. Yu, et al., “PAFAH2 Suppresses Synchronized Ferroptosis to Ameliorate Acute Kidney Injury,” Nature Chemical Biology 20, no. 7 (2024): 835-846.

[6] R. You, Y. Li, Y. Jiang, et al., “WWP2 Deletion Aggravates Acute Kidney Injury by Targeting CDC20/Autophagy Axis,” Journal of Advanced Research (2024).

[7] N. Zheng and N. Shabek, “Ubiquitin Ligases: Structure, Function, and Regulation,” Annual Review of Biochemistry 86 (2017): 129-157.

[8] Y. Huang, Y. Xiao, X. Zhang, X. Huang, and Y. Li, “The Emerging Roles of Tripartite Motif Proteins (TRIMs) in Acute Lung Injury,” Journal of Immunology Research 2021 (2021): 1007126.

[9] J. Chen, X. Feng, X. Zhou, and Y. Li, “Role of the Tripartite Motif-Containing (TRIM) Family of Proteins in Insulin Resistance and Related Disorders,” Diabetes, Obesity & Metabolism 26, no. 1 (2024): 3-15.

[10] Y. Li, X. Huang, F. Guo, et al., “TRIM65 E3 Ligase Targets VCAM-1 Degradation to Limit LPS-Induced Lung Inflammation,” Journal of Molecular Cell Biology 12, no. 3 (2020): 190-201.

[11] X. F. Ma, Y. R. Zhou, Z. X. Zhou, et al., “TRIM65 Suppresses oxLDL-Induced Endothelial Inflammation by Interaction With VCAM-1 in Atherogenesis,” Current Medicinal Chemistry 31, no. 30 (2024): 4898-4911.

[12] T. Tang, L. i. P. X. Zhou, et al., “The E3 Ubiquitin Ligase TRIM65 Negatively Regulates Inflammasome Activation Through Promoting Ubiquitination of NLRP3,” Frontiers in Immunology 12 (2021): 741839.

[13] J. Luo, Y. Luo, J. Chen, et al., “Intestinal Metabolite UroB Alleviates Cerebral Ischemia/Reperfusion Injury by Promoting Competition Between TRIM65 and TXNIP for Binding to NLRP3 Inflammasome in Response to Neuroinflammation,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1870, no. 4 (2024): 167056.

[14] Y. Huang, T. Chen, M. Jiang, et al., “E3 Ligase TRIM65 Alleviates Intestinal Ischemia/Reperfusion Injury Through Inhibition of TOX4-Mediated Apoptosis,” Cell Death & Disease 15, no. 1 (2024): 29.

[15] S. Wei, X. Huang, Q. Zhu, et al., “TRIM65 Deficiency Alleviates Renal Fibrosis Through NUDT21-Mediated Alternative Polyadenylation,” Cell Death and Differentiation 31, no. 11 (2024): 1422-1438.

[16] X. Li, J. Pan, H. Li, et al., “DsbA-L Interacts With VDAC1 in Mitochondrion-Mediated Tubular Cell Apoptosis and Contributes to the Progression of Acute Kidney Disease,” EBioMedicine 76 (2022): 103859.

[17] G. Nowak, J. Megyesi, and W. J. Craigen, “Deletion of VDAC1 Hinders Recovery of Mitochondrial and Renal Functions After Acute Kidney Injury,” Biomolecules 10, no. 4 (2020): 585.

[18] M. E. French, C. F. Koehler, and T. Hunter, “Emerging Functions of Branched Ubiquitin Chains,” Cell Discovery 7, no. 1 (2021): 6.

[19] K. N. Swatek and D. Komander, “Ubiquitin Modifications,” Cell Research 26, no. 4 (2016): 399-422.

[20] Y. Xiao, R. Liu, N. Li, Y. Li, and X. Huang, “Role of the Ubiquitin-Proteasome System on Macrophages in the Tumor Microenvironment,” Journal of Cellular Physiology 239, no. 2 (2024): e31180.

[21] L. D. Zorova, V. A. Popkov, E. Y. Plotnikov, et al., “Mitochondrial Membrane Potential,” Analytical Biochemistry 552 (2018): 50-59.

[22] W. Y. Ding, V. Kuzmuk, S. Hunter, et al., “Adeno-Associated Virus Gene Therapy Prevents Progression of Kidney Disease in Genetic Models of Nephrotic Syndrome,” Science Translational Medicine 15, no. 708 (2023): eabc8226.

[23] A. D. Cowan and A. Ciulli, “Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons From Nature and the Laboratory,” Annual Review of Biochemistry 91 (2022): 295-319.

[24] L. Yang and H. Xia, “TRIM Proteins in Inflammation: From Expression to Emerging Regulatory Mechanisms,” Inflammation 44, no. 3 (2021): 811-820.

[25] P. Duann, H. Li, P. Lin, et al., “MG53-Mediated Cell Membrane Repair Protects Against Acute Kidney Injury,” Science Translational Medicine 7, no. 279 (2015): 279ra236.

[26] X. Sun, N. Huang, P. Li, et al., “TRIM21 Ubiquitylates GPX4 and Promotes Ferroptosis to Aggravate Ischemia/Reperfusion-Induced Acute Kidney Injury,” Life Sciences 321 (2023): 121608.

[27] X. K. Li, X. Z. Xu, Q. Cong, et al., “Tri-Domain Proteins 27 Reduce Inflammation and Apoptosis in HK-2 Cells and Protect Against Acute Kidney Injury in Mice,” European Review for Medical and Pharmacological Sciences 24, no. 23 (2020): 12258-12266.

[28] Y. F. Yang, M. F. Zhang, Q. H. Tian, and C. Z. Zhang, “TRIM65 Triggers Beta-Catenin Signaling via Ubiquitylation of Axin1 to Promote Hepatocellular Carcinoma,” Journal of Cell Science 130, no. 18 (2017): 3108-3115.

[29] Y. Wang and Q. Zhang, “Long Noncoding RNA MALAT1 Knockdown Inhibits Proliferation, Migration, and Invasion and Promotes Apoptosis in Non-Small-Cell Lung Cancer Cells Through Regulating miR-515-3p/TRIM65 Axis,” Cancer Biotherapy & Radiopharmaceuticals (2020).

[30] X. Zeng, X. Deng, Y. Ni, et al., “LPS Inhibits TRIM65 Expression in Macrophages and C57BL/6J Mouse by Activating the ERK1/2 Signaling Pathway,” Experimental and Therapeutic Medicine 25, no. 4 (2023): 188.

[31] Q. Zhang, Y. Li, Q. Zhu, et al., “TRIM65 Promotes Renal Cell Carcinoma Through Ubiquitination and Degradation of BTG3,” Cell Death & Disease 15, no. 5 (2024): 355.

[32] C. Tang, J. Cai, X. M. Yin, J. M. Weinberg, M. A. Venkatachalam, and Z. Dong, “Mitochondrial Quality Control in Kidney Injury and Repair,” Nature Reviews Nephrology 17, no. 5 (2021): 299-318.

[33] H. H. Szeto, “Pharmacologic Approaches to Improve Mitochondrial Function in AKI and CKD,” Journal of the American Society of Nephrology 28, no. 10 (2017): 2856-2865.

[34] H. Hu, L. Guo, J. Overholser, and X. Wang, “Mitochondrial VDAC1: A Potential Therapeutic Target of Inflammation-Related Diseases and Clinical Opportunities,” Cells 11, no. 19 (2022): 3174.

[35] A. Magri, S. Reina, and V. De Pinto, “VDAC1 as Pharmacological Target in Cancer and Neurodegeneration: Focus on Its Role in Apoptosis,” Frontiers in Chemistry 6 (2018): 108.

[36] Y. T. Wang, T. Y. Liu, C. H. Shen, et al., “K48/K63-Linked Polyubiquitination of ATG9A by TRAF6 E3 Ligase Regulates Oxidative Stress-Induced Autophagy,” Cell Reports 38, no. 8 (2022): 110354.

[37] X. Chen, Q. Zhao, Y. Xu, et al., “E3 Ubiquitin Ligase MID1 Ubiquitinates and Degrades Type-I Interferon Receptor 2,” Immunology 167, no. 3 (2022): 398-412.

[38] S. Geisler, K. M. Holmstrom, D. Skujat, et al., “PINK1/Parkin-Mediated Mitophagy Is Dependent on VDAC1 and p62/SQSTM1,” Nature Cell Biology 12, no. 2 (2010): 119-131.

[39] S. J. Ham, D. Lee, H. Yoo, K. Jun, H. Shin, and J. Chung, “Decision Between Mitophagy and Apoptosis by Parkin via VDAC1 Ubiquitination,” PNAS 117, no. 8 (2020): 4281-4291.

[40] N. N. Wu, L. Wang, L. Wang, et al., “Site-Specific Ubiquitination of VDAC1 Restricts Its Oligomerization and Mitochondrial DNA Release in Liver Fibrosis,” Experimental & Molecular Medicine 55, no. 1 (2023): 269-280.

[41] Y. Dong, Q. Zhang, J. Wen, et al., “Ischemic Duration and Frequency Determines AKI-to-CKD Progression Monitored by Dynamic Changes of Tubular Biomarkers in IRI Mice,” Frontiers in Physiology 10 (2019): 153.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.